

AHCL/ SE/ 56 /2020-21

February 11 2021

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001
Symbol : AMRUTANJAN	Scrip Code: 590006

Dear Sir / Madam,

Sub: Outcome of the Board Meeting

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today (**February 11, 2021**) had inter-alia:

- (i) Approved the Un-audited Financial Results for the quarter ended December 31, 2020. The same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Declared Second Interim Dividend of Re.0.80/- per share for the financial year 2020-21 on the Equity Shares of the Company.

The Board Meeting commenced at 11.00 A.M. and concluded at **13:40 P.M.** Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Amrutanjan Health Care Limited**

(M Srinivasan)
Company Secretary & Compliance Officer



Encl:

1. Un-audited Standalone Financials Results for the quarter ended December 31 2020
2. Limited Review Report

Amrutanjan Health Care Limited

103, (Old No. 42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel : +91-44 - 2499 4465
+91-44 - 2466 9000
Fax : +91-44 - 2499 4585

E-mail : customercare@amrutanjan.com
Web Site : www.amrutanjan.com
Toll Free No. : 1 - 800 - 425 - 4545
CIN - L24231TN1936PLC000017

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Statement of Unaudited Financial Results for the quarter and nine months ended 31 December 2020

(Rs. in Lakhs)

Particulars	Quarter ended			Period ended		Year ended
	31 December 2020 (Unaudited)	30 September 2020 (Unaudited)	31 December 2019 (Unaudited)	31 December 2020 (Unaudited)	31 December 2019 (Unaudited)	31 March 2020 (Audited)
I Income from operations						
Revenue from operations	10,009.70	9,211.17	8,275.40	23,882.72	20,215.76	26,147.67
II Other income	254.48	404.87	226.15	863.91	568.04	832.13
III Total income (I + II)	10,264.18	9,616.04	8,501.55	24,746.63	20,783.80	26,979.80
IV Expenses						
(a) Cost of materials consumed	3,139.31	2,592.95	2,578.88	6,427.05	6,690.48	8,805.65
(b) Purchases of stock-in-trade	988.68	1,371.40	894.08	2,827.61	2,827.61	3,598.92
(c) Changes in inventories of finished goods, work in progress and stock in trade	(116.01)	(141.24)	140.77	713.54	(67.43)	(697.45)
(d) Employee benefits expense	1,055.31	981.42	986.69	2,951.20	2,957.45	3,936.48
(e) Advertisement and selling expenditure	1,554.12	829.75	1,764.59	2,739.47	3,445.98	4,350.46
(f) Finance cost	4.29	4.52	4.67	13.29	14.89	22.10
(g) Depreciation and amortisation expense	84.41	88.75	122.25	267.97	333.86	435.94
(h) Other expenses	739.76	749.62	749.78	1,987.20	2,199.41	3,082.31
Total expenses (IV)	7,449.87	6,477.17	7,241.71	17,927.33	18,402.25	23,534.41
V Profit before tax (III - IV)	2,814.31	3,138.87	1,259.84	6,819.30	2,381.55	3,445.39
VI Tax expenses	715.75	783.99	310.56	1,723.14	662.41	937.06
VII Profit for the period (V - VI)	2,098.56	2,354.88	949.28	5,096.16	1,719.14	2,508.33
VIII Other comprehensive income						
Re-measurement (losses) / gain on defined benefit plans, net of taxes	(21.23)	16.62	4.89	(7.48)	(29.02)	(29.37)
Total other comprehensive income/(loss) for the period	(21.23)	16.62	4.89	(7.48)	(29.02)	(29.37)
IX Total comprehensive income for the period (VII + VIII)	2,077.33	2,371.50	954.17	5,088.68	1,690.12	2,478.96
Paid-up equity share capital (Face value Re. 1/- each)	292.31	292.31	292.31	292.31	292.31	292.31
Basic and diluted earnings per share	7.18 (not annualised)	8.06 (not annualised)	3.25 (not annualised)	17.43 (not annualised)	5.88 (not annualised)	8.58 (annualised)
See accompanying notes to financial results						

Handwritten signature



AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Notes:

1. The above financial results for the quarter and nine months ended 31 December 2020 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 11 February 2021. The above results have been subjected to limited review by the statutory auditor of the Company. The auditors have issued an unmodified review report.


2. The financial results has been prepared in accordance with recognition and measurement principles laid down in accordance with the Indian Accounting Standard ('Ind AS'), 34 - "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations 2015.

3. Interim dividend of INR 0.8 per share (80% on par value of INR 1 each), aggregating to INR 233.85 lakhs has been paid during the quarter ended 31 December 2020.

4. Segment reporting in the financial results: Based on the 'management approach' as defined in Ind AS 108 "Operating Segments", the Chief Operating Decision Maker evaluates the Company's performance as OTC Products and Beverages.

Particulars	Quarter ended			Period ended		Year ended
	31 December 2020 (Unaudited)	30 September 2020 (Unaudited)	31 December 2019 (Unaudited)	31 December 2020 (Unaudited)	31 December 2019 (Unaudited)	31 March 2020 (Audited)
1 Segment revenue						
a OTC Products	9,721.88	8,903.70	8,051.90	22,929.34	18,760.40	24,077.67
b Beverages	232.69	277.01	165.33	658.85	1,264.17	1,829.92
c Others	55.13	30.46	58.17	94.52	191.19	240.08
Total	10,009.70	9,211.17	8,275.40	23,882.72	20,215.76	26,147.67
2 Segment results						
a OTC Products	2,663.42	2,968.30	1,176.42	6,495.44	2,239.55	3,177.02
b Beverages	(60.04)	(150.55)	(66.42)	(265.81)	(148.41)	(155.22)
c Others	(21.42)	(25.50)	(81.28)	(84.34)	(151.99)	(191.06)
Total	2,581.96	2,792.25	1,028.72	6,125.29	1,939.15	2,829.74
Less :						
i) Finance cost	4.29	4.52	4.67	13.29	14.89	22.10
ii) Other unallocable expenditure net of unallocable income	(236.64)	(351.14)	(235.79)	(707.30)	(457.29)	(637.75)
Total profit before tax	2,814.31	3,138.87	1,258.84	6,819.30	2,381.55	3,445.39
3 Segment assets						
a OTC Products	4,922.66	4,486.02	7,704.92	4,922.66	7,704.92	6,934.96
b Beverages	881.21	891.72	1,024.84	881.21	1,024.84	1,131.32
c Others	105.82	114.46	49.96	105.82	49.96	101.60
d Unallocated assets	21,201.34	19,036.81	11,792.99	21,201.34	11,792.99	12,466.72
Total	27,111.03	24,528.81	20,572.71	27,111.03	20,572.71	20,534.52
4 Segment liabilities						
a OTC Products	4,788.40	4,126.39	4,075.67	4,788.40	4,075.67	3,505.77
b Beverages	452.73	482.71	318.12	452.73	318.12	628.25
c Others	105.26	110.88	105.85	105.26	105.85	-
d Unallocated liabilities	946.67	854.92	372.95	946.67	372.96	457.94
Total	6,293.06	5,574.90	4,872.60	6,293.06	4,872.60	4,591.96
Total capital employed in the Company	20,817.97	18,953.91	15,699.91	20,817.97	15,699.91	15,942.56

For Amrutanjan Health Care Limited



S Sambhu Prasad
Chairman & Managing Director

Date: 11 February 2021
Place: Chennai

B S R & Co. LLP

Chartered Accountants

KRM Tower, 1st & 2nd Floors,
No.1, Harrington Road, Chetpet,
Chennai - 600 031, India

Telephone: + 91 44 4608 3100
Fax: + 91 44 4608 3199


To
Board of Directors of Amrutanjan Health Care Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Amrutanjan Health Care Limited** for the quarter ended and year to date results for the period from 1 April 2020 to 31 December 2020 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for B S R & Co. LLP

Chartered Accountants

Firm's Registration No.: 101248W/W-100022


K Raghuram

Partner

Membership No.: 211171

UDIN: 21211171AAAAAE6119

Place: Chennai

Date: 11 February 2021

Registered Office:

14th Floor, Central B Wing and Near: C Wing, NESCO IT Park,
4, NESCO Center, Western Express Highway, Goregaon,
East, Mumbai - 400063